Outside of China, other Asian biotech hubs have early ambitions, too

APAC territories beyond Australia and China have yet to become magnets for first-in-human trials. But several Asian hubs are trying to secure earlier roles in global development, drawing on different combinations of regulatory reform, clinical infrastructure, patient access, and government support.

The initiatives in Singapore, South Korea and Taiwan show that the opportunity outside China and Australia is not simply a race to become the next FIH magnet. Rather, each is trying to give sponsors compelling reasons to include its market earlier...